NCT01570387View on ClinicalTrials.gov

A Phase I/II Trial of Pomalidomide and Dexamethasone in Subjects With Previously-Treated AL Amyloidosis

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

June 30, 2012

Primary Completion Date

November 30, 2018

Study Completion Date

April 30, 2019

Conditions
AL Amyloidosis
Interventions
DRUG

Pomalidomide

Cohort 1 = 2 mg/day, Cohort 2 = 3 mg/day, Cohort 3 = 4 mg/day: Days 1-21 of a 28 day cycle

DRUG

Dexamethasone

10-20 mg on days 1, 8, 15, and 22

Trial Locations (1)

02118

Boston Medical Center, Boston

Sponsors

Collaborators (1)

Celgene Corporation
All Listed Sponsors
collaborator

Celgene Corporation

INDUSTRY

lead

Boston Medical Center

OTHER